Afficher la notice abrégée

Recommendations of the schizophrenia expert center network for the screening prevention and treatment of sleep disorders based on the results from the real-world schizophrenia FACE-SZ national cohort

dc.rights.licenseopenen_US
dc.contributor.authorSUNHARY DE VERVILLE, P.L.
dc.contributor.authorETCHECOPAR-ETCHART, D.
dc.contributor.authorRICHIERI, Raphaelle
dc.contributor.authorGODIN, O.
dc.contributor.authorSCHURHOFF, Franck
dc.contributor.authorBERNA, Fabrice
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorAOUIZERATE, Bruno
dc.contributor.authorCAPDEVIELLE, Delphine
dc.contributor.authorCHEREAU, Isabelle
dc.contributor.authorD'AMATO, Thierry
dc.contributor.authorDUBERTRET, Caroline
dc.contributor.authorDUBREUCQ, Julien
dc.contributor.authorLEIGNIER, S.
dc.contributor.authorMALLET, Jasmina
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorMISDRAHI, David
dc.contributor.authorPASSERIEUX, Catherine
dc.contributor.authorPIGNON, B.
dc.contributor.authorREY, Romain
dc.contributor.authorURBACH, Mathieu
dc.contributor.authorVIDAILHET, P.
dc.contributor.authorLEBOYER, Marion
dc.contributor.authorLLORCA, Pierre-Michel
dc.contributor.authorLANCON, Christophe
dc.contributor.authorBOYER, L.
dc.contributor.authorFOND, Guillaume
dc.contributor.authorTHE FACE-SZ (FONDAMENTAL ACADEMI CENTERS, Of Expertise For Schizophrenia), Group
dc.date.accessioned2021-10-19T15:06:14Z
dc.date.available2021-10-19T15:06:14Z
dc.date.issued2021
dc.identifier.issn0278-5846en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/112818
dc.description.abstractEnBackground: Sleep disorders associated factors are under explored in schizophrenia while the literature suggests high and heterogeneous frequency. Aims: The objective of the present study was to determine the prevalence and risk factors of sleep disorders in the real-world FACE-SZ national cohort. Method: Stabilized schizophrenic outpatients were recruited in 10 expert centers for schizophrenia. Sleep quality was explored with the Pittsburgh Sleep Quality Index (PSQI) and sleep disorders was defined by a PSQI score > 5. Psychosis severity was measured with the Positive and Negative Syndrome Scale, current major depressive episode with the Calgary Depression Scale for Schizophrenia, verbal aggressiveness with the Buss-Perry Aggression Questionnaire, adherence to treatment with the Medication Adherence Rating Scale, akathisia with the Barnes Akathisia Scale. Current somatic comorbidities and body mass index were reported. Variables with P values <0.20 in univariate analysis were included in a multivariate regression model. Results: Of the 562 included patients, 327 subjects (58.2%, IC95% [54.1% - 62.3%]) reported having sleep disorders. After adjustment, sleep disorders were significantly associated with migraine (adjusted odds ratio aOR = 2.23, p = 0.041), major depressive disorder (aOR 1.79, p = 0.030), poor adherence to treatment (aOR = 0.87, p = 0.006), akathisia (aOR = 1.29, p = 0.042) and verbal aggressiveness (aOR = 1.09, p = 0.002). Conclusions: More than one on two stabilized real-life outpatients with schizophrenia have been identified with sleep disorders. Combined with the literature data, we have yielded expert recommendations for the treatment and prevention of sleep disorders including treating undiagnosed comorbid depression and migraine and managing antipsychotic treatment to improve adherence and akathisia.
dc.description.sponsorshipSorbonne Universités à Paris pour l'Enseignement et la Rechercheen_US
dc.description.sponsorshipFondaMental-Cohortesen_US
dc.language.isoENen_US
dc.subject.enFACE-SZ
dc.subject.enMajor depressive disorder
dc.subject.enMigraine
dc.subject.enPSQI
dc.subject.enPsychiatry
dc.subject.enSchizophrenia
dc.subject.enSleep disorders
dc.title.enRecommendations of the schizophrenia expert center network for the screening prevention and treatment of sleep disorders based on the results from the real-world schizophrenia FACE-SZ national cohort
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.pnpbp.2021.110275en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed33582207en_US
bordeaux.journalProgress in Neuro-Psychopharmacology and Biological Psychiatryen_US
bordeaux.volume110en_US
bordeaux.hal.laboratoriesNutriNeurO (Laboratoire de Nutrition et Neurobiologie Intégrée) - UMR 1286en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINRAEen_US
bordeaux.institutionCNRS
bordeaux.teamPsychoneuroimmunologie et Nutrition: Approches expérimentales et cliniquesen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDFondation FondaMentalen_US
bordeaux.identifier.funderIDAgence Nationale de la Rechercheen_US
hal.identifierhal-03386085
hal.version1
hal.date.transferred2021-10-19T15:06:27Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Progress%20in%20Neuro-Psychopharmacology%20and%20Biological%20Psychiatry&amp;rft.date=2021&amp;rft.volume=110&amp;rft.eissn=0278-5846&amp;rft.issn=0278-5846&amp;rft.au=SUNHARY%20DE%20VERVILLE,%20P.L.&amp;ETCHECOPAR-ETCHART,%20D.&amp;RICHIERI,%20Raphaelle&amp;GODIN,%20O.&amp;SCHURHOFF,%20Franck&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée